Abstract
Background. OM is a common toxicity of conditioning regimens for HSCT that has been associated with adverse clinical and economic outcomes.
Methods. A retrospective chart review study of ~400 consecutive HSCT recipients was undertaken at a single academic center. OM severity was assessed across eight oropharyngeal sites using a validated scale which was scored as follows: no erythema/ulceration = 0; erythema only = I; ulceration one site = II; two sites = III; three sites= IV; and four or more sites = V. OM assessments began on the day of conditioning and continued bi-weekly until hospital discharge. Outcomes of interest included number of days of fever, total parenteral nutrition (TPN), and parenteral narcotic therapy, incidence of grade III or IV (Common Toxicity Criteria) infection, and inpatient days and charges. We report data here for the 115 MM patients in the study cohort who underwent AU HSCT after high-dose MP conditioning.
Results. Mean age was 54 yrs. Seventeen percent of patients received total body irradiation. Bone marrow was the source of most grafts. Forty-eight percent of patients experienced OM ≥ grade II. The relationship between worst recorded grade of OM and each of the outcomes of interest is reported below.
Conclusions. OM is associated with worse clinical and economic outcomes in MM patients undergoing AU HSCT following high-dose MP conditioning.
. | Worst Grade of OM (N=115) . | ||||||
---|---|---|---|---|---|---|---|
. | 0 . | I . | II . | III . | IV . | V . | . |
*mean, SD; **test for linear trend; Cochran-Armitage for dichotomous measures, GLM for continuous measures | |||||||
Outcome | n=37 | n=23 | n=24 | n=15 | n=8 | n=8 | -value p |
Fever days* | 1.2 (2.8) | 2.5 (3.1) | 2.1 (2.3) | 1.9 (1.4) | 3.0 (2.1) | 3.6 (6.2) | 0.057 |
TPN days* | 0.0 (0.0) | 0.1 (0.4) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 2.3 (6.0) | 0.003 |
Narcotic days* | 1.5 (3.1) | 4.7 (3.8) | 4.6 (4.4) | 4.4 (3.7) | 7.9 (3.3) | 9.9 (7.4) | <0.001 |
Infection, % | 51.4 | 73.9 | 62.5 | 80.0 | 100.0 | 75.0 | 0.014 |
Mortality, % | 0.0 | 0.0 | 4.2 | 0.0 | 0.0 | 12.5 | 0.085 |
Inpatient days* | 18.6 (3.4) | 21.0 (3.5) | 19.6 (3.6) | 19.7 (2.3) | 23.3 (2.4) | 23.4 (5.6) | <0.001 |
Inpatient charges* (x 1,000 USD) | 119 (36) | 130 (35) | 118 (25) | 121 (28) | 141 (31) | 184 (92) | <0.001 |
. | Worst Grade of OM (N=115) . | ||||||
---|---|---|---|---|---|---|---|
. | 0 . | I . | II . | III . | IV . | V . | . |
*mean, SD; **test for linear trend; Cochran-Armitage for dichotomous measures, GLM for continuous measures | |||||||
Outcome | n=37 | n=23 | n=24 | n=15 | n=8 | n=8 | -value p |
Fever days* | 1.2 (2.8) | 2.5 (3.1) | 2.1 (2.3) | 1.9 (1.4) | 3.0 (2.1) | 3.6 (6.2) | 0.057 |
TPN days* | 0.0 (0.0) | 0.1 (0.4) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 2.3 (6.0) | 0.003 |
Narcotic days* | 1.5 (3.1) | 4.7 (3.8) | 4.6 (4.4) | 4.4 (3.7) | 7.9 (3.3) | 9.9 (7.4) | <0.001 |
Infection, % | 51.4 | 73.9 | 62.5 | 80.0 | 100.0 | 75.0 | 0.014 |
Mortality, % | 0.0 | 0.0 | 4.2 | 0.0 | 0.0 | 12.5 | 0.085 |
Inpatient days* | 18.6 (3.4) | 21.0 (3.5) | 19.6 (3.6) | 19.7 (2.3) | 23.3 (2.4) | 23.4 (5.6) | <0.001 |
Inpatient charges* (x 1,000 USD) | 119 (36) | 130 (35) | 118 (25) | 121 (28) | 141 (31) | 184 (92) | <0.001 |
Author notes
Corresponding author